Eli Lilly to acquire Scorpion Therapeutics’ STX-478 program for up to $2.5B
Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha ...
Ibj.com16d
Lilly acquires Scorpion Therapeutics in deal worth up to $2.5B
The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors. The therapy is designed to target ...
precisionmedicineonline15d
Eli Lilly to Acquire Scorpion Therapeutics' Mutant PI3Kα Inhibitor for $2.5B
NEW YORK – Eli Lilly on Monday said it will acquire Scorpion Therapeutics' mutant-PI3Kα inhibitor STX-478 for up to $2.5 billion while Scorpion spins out a new entity to develop its non-PI3Kα assets.
Wall Street Journal16d
Eli Lilly to Buy Scorpion Therapeutics Drug Program in $2.5 Billion Deal
The drugmaker said Monday it is acquiring Scorpion and its STX-478 program, with shareholders of the private company set to receive up to $2.5 billion in an upfront payment and subsequent payments ...
Eli Lilly to acquire Scorpion for up to $2.5B
Eli Lilly (NYSE:LLY) has agreed to buy Scorpion Therapeutics' lead drug program for up to $2.5B in cash and spin out the remaining company as a new entity. Read more here.
Yahoo Finance16d
Eli Lilly targets Scorpion Therapeutics to expand reach in oncology
Lilly’s bid to acquire Scorpion was driven by the Scorpion’s PI3Kα inhibitor program that is centered on the drug STX-478. The drug is in clinical studies evaluating its potential in solid ...